Gansu Longshenrongfa Pharmaceutical Industry Co Ltd
Gansu Longshenrongfa Pharmaceutical Industry CO.,LTD researches, develops, produces, and sells traditional Chinese medicines, medical devices, and health products in China and internationally. It also engages in the cultivation, processing, and sale of chemical drugs and medicinal herbs, as well as pharmaceutical distribution, testing, and inspection services. The company was founded in 2002 and … Read more
Gansu Longshenrongfa Pharmaceutical Industry Co Ltd (300534) - Total Liabilities
Latest total liabilities as of September 2025: CN¥567.12 Million CNY
Based on the latest financial reports, Gansu Longshenrongfa Pharmaceutical Industry Co Ltd (300534) has total liabilities worth CN¥567.12 Million CNY as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Gansu Longshenrongfa Pharmaceutical Industry Co Ltd - Total Liabilities Trend (2011–2024)
This chart illustrates how Gansu Longshenrongfa Pharmaceutical Industry Co Ltd's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Gansu Longshenrongfa Pharmaceutical Industry Co Ltd Competitors by Total Liabilities
The table below lists competitors of Gansu Longshenrongfa Pharmaceutical Industry Co Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Renxin New Material Co. Ltd. A
SHE:301395
|
China | CN¥452.64 Million |
|
HEBA Fastighets AB (publ)
ST:HEBA-B
|
Sweden | Skr8.20 Billion |
|
BRAZIL RES
F:BSR
|
Germany | €4.47 Million |
|
Jiangxi JDL Environmental Protection Co. Ltd. A
SHG:688057
|
China | CN¥362.02 Million |
|
Favite Inc
TW:3535
|
Taiwan | NT$616.49 Million |
|
Changzhou Tiansheng New Materials Co Ltd
SHE:300169
|
China | CN¥804.73 Million |
|
Rongyu Group Co Ltd
SHE:002622
|
China | CN¥1.04 Billion |
Liability Composition Analysis (2011–2024)
This chart breaks down Gansu Longshenrongfa Pharmaceutical Industry Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.60 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.82 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.43 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Gansu Longshenrongfa Pharmaceutical Industry Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Gansu Longshenrongfa Pharmaceutical Industry Co Ltd (2011–2024)
The table below shows the annual total liabilities of Gansu Longshenrongfa Pharmaceutical Industry Co Ltd from 2011 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | CN¥674.39 Million | +7.88% |
| 2023-12-31 | CN¥625.14 Million | +317.70% |
| 2022-12-31 | CN¥149.66 Million | +64.03% |
| 2021-12-31 | CN¥91.24 Million | -28.46% |
| 2020-12-31 | CN¥127.53 Million | +78.96% |
| 2019-12-31 | CN¥71.26 Million | +23.54% |
| 2018-12-31 | CN¥57.68 Million | -17.64% |
| 2017-12-31 | CN¥70.04 Million | +17.24% |
| 2016-12-31 | CN¥59.74 Million | -75.23% |
| 2015-12-31 | CN¥241.17 Million | +108.99% |
| 2014-12-31 | CN¥115.40 Million | -14.54% |
| 2013-12-31 | CN¥135.04 Million | +9.73% |
| 2012-12-31 | CN¥123.07 Million | +63.77% |
| 2011-12-31 | CN¥75.15 Million | -- |